Clinical Trial Update: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the ERK1/2 inhibitor BVD-523 (ulixertinib) in patients with acute myeloid leukemia or myelodysplastic syndromes; the trial is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• BVD-523 (Ulixertinib) (ulixertinib)

Snippet

Sponsor: BioMed Valley Discoveries, Inc | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-09-05